Amphastar Pharmaceuticals (AMPH) Stock Statistics & Valuation Metrics

Amphastar Pharmaceuticals has a market cap or net worth of $905.59M. The enterprise value is $796.58M.

Amphastar Pharmaceuticals has 45,370,170 shares outstanding. The number of shares has decreased by -2.65% in one year.

Amphastar Pharmaceuticals’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 7.52%.

The current PE Ratio of Amphastar Pharmaceuticals is 12.6. Amphastar Pharmaceuticals’s PEG ratio is -0.35.

In the last 12 months, Amphastar Pharmaceuticals had revenue of 719.89M and earned 98.09M in profits. Earnings per share was 2.10.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Amphastar Pharmaceuticals pays an annual dividend of $0.3, resulting in a dividend yield of ―

Amphastar Pharmaceuticals upcoming earnings date is May 13, 2026, After Close (Confirmed).

Amphastar Pharmaceuticals as a current ratio of 4.02, with Debt / Equity ratio of 5.99%

In the past 12 months, Amphastar Pharmaceuticals has paid 25.53M in taxes.

Amphastar Pharmaceuticals EV to EBITDA ratio is 7.57, with an EV/FCF ratio of 9.31.

Amphastar Pharmaceuticals has $282.81M in cash and marketable securities with $47.25M in debt, giving a net cash position of $235.56M billion.

Gross margin is 49.46%, with operating margin of 19.50%, and net profit margin of 13.63%.

The average price target for Amphastar Pharmaceuticals is $31.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy